STOCK TITAN
  1. Home
  2. Sec-filings
  3. MPLT
  4. [Form 4] MapLight Therapeutics, Inc. Insider Trading Activity

MapLight Therapeutics (MPLT) grants options and RSUs to interim CFO

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. (MPLT) reported equity awards to its CAO and Interim CFO, Jonathan Gillis. On August 17, 2026 he received two stock option grants to purchase a total of 27,268 shares of voting common stock at an exercise price of $11.245 per share, expiring on August 16, 2036, with vesting in quarterly or monthly installments subject to continued service. He also received two restricted stock unit awards totaling 8,242 RSUs, each RSU representing one share of voting common stock, vesting over multi-year quarterly schedules, also contingent on continued service.

Positive

  • None.

Negative

  • None.
Insider GILLIS JONATHAN
Role CAO and Interim CFO
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) F4 24,455 $0.00 $0.00
Grant/Award Employee Stock Option (Right to Buy) F5 2,813 $0.00 $0.00
Grant/Award Voting Common Stock F1, F2 6,020 $0.00 $0.00
Grant/Award Voting Common Stock F3, F2 2,222 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (right to buy) — 27,268 shares (Direct); Voting Common Stock — 152,482 shares (Direct)
Footnotes (5)
  1. F1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
  2. F2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
  3. F3. Represents an RSU award. The RSUs shall vest in 8 equal quarterly installments commencing on October 1, 2026, subject to the Reporting Person's continued service through each vesting date.
  4. F4. 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.
  5. F5. The option share vest in 24 equal monthly installments commencing on August 1, 2026, subject to the Reporting Person's continued service through each vesting date.
Option grant 1 shares 24,455 shares Employee Stock Option (right to buy) granted on August 17, 2026
Option grant 2 shares 2,813 shares Employee Stock Option (Right to Buy) granted on August 17, 2026
Option exercise price $11.245 per share Conversion or exercise price for both option grants
Option expiration August 16, 2036 Expiration date for both option grants
RSU grant 1 6,020 RSUs Restricted stock unit award vesting from July 1, 2027 in quarterly tranches
RSU grant 2 2,222 RSUs Restricted stock unit award vesting in 8 equal quarterly installments from October 1, 2026
Initial RSU vest date (grant 1) July 1, 2027 1/4 of RSUs in the 6,020-unit grant vest on this date
Initial RSU vest date (grant 2) October 1, 2026 First of 8 equal quarterly installments for the 2,222-unit grant
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest"
Employee Stock Option (right to buy financial
"security_title": "Employee Stock Option (right to buy)"
vesting financial
"RSUs shall vest in 8 equal quarterly installments commencing on October 1, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
voting common stock financial
"receive one share of voting common stock of the Issuer"

FAQ

What equity awards did MPLT grant to Jonathan Gillis on August 17, 2026?
MapLight Therapeutics granted Jonathan Gillis two stock option awards for 27,268 shares at $11.245 and two RSU awards totaling 8,242 shares. All awards vest over time, contingent on his continued service with the company.

What are the terms of the MPLT stock options granted to Jonathan Gillis?
Jonathan Gillis received options for 24,455 and 2,813 shares at an exercise price of $11.245 per share, expiring on August 16, 2036. Vesting occurs in quarterly or monthly installments, subject to his continued service at each vesting date.

How do the MPLT RSU awards to Jonathan Gillis vest?
One RSU grant of 6,020 units vests 1/4 on July 1, 2027, then 1/16 on each October 1, January 1, April 1, and July 1 thereafter. A second grant of 2,222 RSUs vests in 8 equal quarterly installments starting October 1, 2026.

What does each RSU granted by MPLT to Jonathan Gillis represent?
Each restricted stock unit granted to Jonathan Gillis represents a contingent right to receive one share of MapLight Therapeutics’ voting common stock. Delivery of shares depends on satisfaction of the RSU vesting schedule and his continued service.

Are Jonathan Gillis’s MPLT equity awards part of a Rule 10b5-1 trading plan?
No. The filing indicates the Rule 10b5-1 checkbox is not affirmed, meaning these reported awards are not disclosed as granted or transacted pursuant to a Rule 10b5-1 trading plan under the SEC’s form framework.

Did Jonathan Gillis sell any MPLT shares in this Form 4 filing?
No sales are reported. The Form 4 shows only acquisitions of derivative and non-derivative awards—stock options and RSUs—granted at no cash purchase price, with no dispositions or exercises disclosed in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GILLIS JONATHAN
(Last)(First)(Middle)
C/O MAPLIGHT THERAPEUTICS, INC.
800 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CAO and Interim CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Voting Common Stock08/17/2026A6,020(1)A$0(2)150,260D
Voting Common Stock08/17/2026A2,222(3)A$0(2)152,482D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$11.24508/17/2026A24,455 (4)08/16/2036Voting Common Stock24,455$024,455D
Employee Stock Option (Right to Buy)$11.24508/17/2026A2,813 (5)08/16/2036Voting Common Stock2,813$02,813D
Explanation of Responses:
1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
3. Represents an RSU award. The RSUs shall vest in 8 equal quarterly installments commencing on October 1, 2026, subject to the Reporting Person's continued service through each vesting date.
4. 1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.
5. The option share vest in 24 equal monthly installments commencing on August 1, 2026, subject to the Reporting Person's continued service through each vesting date.
/s/ Kristopher L. Hanson, Attorney-in-Fact08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR